Matinas BioPharma $50 Million ATM Program With BTIG Terminated With No Penalties
I'm LongbridgeAI, I can summarize articles.Matinas BioPharma announced the immediate termination of its $50 million At-The-Market (ATM) Sales Agreement with BTIG, effective July 23, 2026. The original agreement, signed in July 2020, allowed the sale of up to $50 million in common stock. BTIG exercised its contractual right to terminate the arrangement without any penalties or fees. This action removes Matinas' current ATM financing option unless a new program is established.
Matinas BioPharma announced the termination of its At-The-Market Sales Agreement with BTIG, effective immediately on July 23, 2026. The agreement, originally signed on July 2, 2020, allowed the company to sell up to $50 million of common stock through at-the-market offerings. BTIG ended the arrangement under its contractual rights, and no termination fees or expenses are due. The change removes this at-the-market financing option unless Matinas establishes a new program.
Agreement details:
- Agreement terminated: At-The-Market Sales Agreement
- Counterparty: BTIG
- Original agreement date: Jul 02 2020
- Termination date: Jul 23 2026
- Termination type: Early
- Exit fees / payments: None
- Reason: BTIG exercised its contractual termination right
Original SEC Filing: Matinas BioPharma Holdings, Inc. [ MTNB ] - 8-K - Jul. 24, 2026